---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Definition and etiology"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Definition and etiology. Topics: Inheritance pattern, Definition: recurrent bradykinin-mediated angioedema, Etiology: dysfunction or lack of C1 esterase inhibitor, Classification: HAE with C1-INH deficiency (types 1 and 2) and HAE with normal C1-INH, and 3 further topics. 7 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Inheritance pattern

> “an autosomal dominant pattern”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.1-2"></a>

### Definition: recurrent bradykinin-mediated angioedema

> “Angioedema is a localized, self-limiting, asymmetric, and disfiguring non-inflammatory edema of the subcutaneous and submucosal tissues that arises because of increased vascular permeability.”
> “HAE comprises a group of genetic disorders characterized by recurrent episodes of angioedema, inherited across generations and typically mediated by bradykinin.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.1-3"></a>

### Etiology: dysfunction or lack of C1 esterase inhibitor

> “Hereditary angioedema (HAE) is a rare disease caused by dysfunction or lack of the C1 esterase inhibitor (C1-INH) protein.”

Source: [Fisch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39827848/)

<a id="topic-2.2.1.1-4"></a>

### Classification: HAE with C1-INH deficiency (types 1 and 2) and HAE with normal C1-INH

> “HAE (ORPHA:91378, OMIM: PS106100) is most commonly caused by a deficiency of C1 inhibitor (C1-INH), which can be confirmed through biochemical and genetic testing.”
> “It is subclassified into type 1 HAE (quantitative deficiency) and type 2 HAE (dysfunctional protein).”
> “Furthermore, in 2000, a new type of HAE was described in patients with normal C1-INH function, a form initially known as HAE type 3 but currently called HAE with normal C1-INH (HAE-nC1-INH).”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.1-5"></a>

### Genetic cause: SERPING1 and F12 variants

> “Variants (also called mutations) in the SERPING1 gene cause hereditary angioedema due to C1-INH deficiency.”
> “SERPING1 gene variants that cause hereditary angioedema due to C1-INH deficiency type I lead to reduced levels of C1-INH in the blood, while variants that cause type II result in the production of a C1-INH protein that functions abnormally.”
> “Variants in the F12 gene cause most cases of hereditary angioedema with normal C1-INH.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.1-6"></a>

### Penetrance, transmission risk, and de novo variants

> “HAE-C1-INH is an autosomal dominant disorder characterized by high penetrance, with only about 5% of mutation carriers remaining asymptomatic over their lifetime.”
> “The risk of parent–child transmission is 50%, but up to 25% of cases result from de novo genetic mutations.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.1-7"></a>

### Distribution of HAE types: Swedish population-based cohort

> “Out of the 239 individuals, the majority had HAE type 1 (90.4%) while 9.6% where characterized as HAE type 2.”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
